Dementia is caused by multiple diseases, most commonly Alzheimers disease, and cannot yet be cured. If we could improve the way to detect important biological processes that lead to dementia, with so-called biomarkers, we can better understand and monitor the underlying diseases, target the disease processes, and diagnose patients. This requires development of technologies to detect and track biomarkers in patients and assess the effect of new therapies. We apply innovative technologies to assess key biological processes affected in dementia (CHIME markers), to develop a framework for non-invasive testing of pharmaceuticals that provide relief in early stages of neurological diseases.